Massimo Masserini - Full Professor
Department and institution: School of Medicine and Surgery, University of Milano Bicocca
tel. +39 02 6448 8203
institutional profile page: UNIMIB
Keywords: Nanomedicine, Alzheimer Disease, Neurodegeneration, Blood-brain barrier, Nanoparticles
Molecular mechanisms of neurodegeneration (Alzheimer's disease, prion diseases); Nanotechnology for the treatment and diagnosis of Alzheimer's disease; Molecular interactions between cells and ligands. Neurochemistry and biophysics of glycosphingolipids; Functions of caveolae and lipid rafts in cell membranes; Metabolism, Aging and lateralization of the Central Nervous System.
Education and formation
1975, Degree in Chemistry, University of Milan ; 1978, Research Associate , Institute of Biochemistry, University of Milano. 1984 - NATO Fellowship for biomedical studies. 1984/1985 -Post-doctoral position, University of Tennessee at Knoxville, USA, study of liposomes for biological applications; ,1985 Assistant professor University of Milano ; 1986- Fellowship of the International Society of Neurochemistry. 1987, 1989 - Visiting Professor at Johns Hopkins University -Baltimore, USA study of liposome-protein interactions. 2000 -Full Professor of Biochemistry, Dept. Health Sciences- University of Milano-Bicocca (current position)
2009-Director of the Center for Nanomedicine of MilanBicocca (NANOMIB).
2013- Member of the Government Board , University Milano Bicocca ;
2006-2012 Head of the Department of Health Sciences.;
2003- 2012 : Director of the School of Specialization in Human Nutrition .
2000-2012 Coordinator of the “Biological membranes” Sectiuon of the Italian Society of Biochemistry and Molecular Biology
He autorshiped about 150 articles, published in the main international and national journals and is inventor of 4 Patents. Referee for several scientific journals and Research Agencies (NIH, INSERM, MIUR); Associate Editor: Nanomedicine NBM (Elsevier).
Member of the Editorial Board Journal of Nanomedicine and Biotherapeutic Discovery (Omics Publishing)
Projects funded in the last 3 years: European Coordinator–FP7 Project: "NAD”Nanoparticles for therapy and diagnosis of Alzheimer's disease". The NAD project has been awarded (2014) by the E.C. among the best completed FP7 program projects. Coordinator, project “Nanoparticles for boosted brain targeting” funded by European Center of Nanomedicine- Coordinator of local Unit, Lombardy Region “Network Enabled Drug Design”. Coordinator of local Unit, Lombardy Region,”Scouting of Technology Transfer “;Participant: Italian Ministry of University: Role of lipid rafts in the processing of Prion protein
Participation in international and national research initiatives and organizations: European Technology Platform of Nanomedicine (EU) ; CMST COST Action TD0802 Dendrimers in Biomedical Applications. Targeted Nano-Pharmaceuticals and Early Diagnostics Cluster (EU) European Centre for Nanomedicine.
1. Bana L, Minniti S, Salvati E, Sesana S, Zambelli V, Cagnotto A, Orlando A, Cazzaniga E, Zwart R, Scheper W, Masserini M, Re F. (2013). Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: Implications for therapy of Alzheimer disease. NANOMEDICINE , S1549-9634(13)00684-9.
2. Orlando A, Re F, Sesana S, Rivolta I, Panariti A, Brambilla D, Nicolas J, Couvreur P, Andrieux K, Masserini M, Cazzaniga E (2013). Effect of nanoparticles binding β-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. . INTERNATIONAL JOURNAL OF NANOMEDICINE, 8, 1335-1347,
3. Mutoh T, Kawamura N, Hirabayashi Y, Shima S, Miyashita T, Ito S, Asakura K, Araki W, Cazzaniga E, Muto E, Masserini M (2012). Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis. FASEB JOURNAL, 26, 3065-3074
4. Le Droumaguet B, Nicolas J, Brambilla D, Mura S, Maksimenko A, De Kimpe L, Salvati E, Zona C, Airoldi C, Canovi M, Gobbi M, Noiray M, La Ferla B, Nicotra F, Scheper W, Flores O, Masserini M, Andrieux K, Couvreur P (2012). Versatile and Efficient Targeting Using a Single Nanoparticulate Platform and its Application to Cancer and Alzheimer's Disease. ACS NANO, 6, 5866-5879
5. Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, Sonnino S, Brogioli D, Musicanti C, Gasco P, Salmona M, Masserini ME (2010) .Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. BIOMATERIALS 31, 6519-29
last update: January 2018